Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.53 |
| ▸ | ARG2 | P78540 | 4/20 | 0.48 |
| ▸ | ARG1 | P05089 | 3/20 | 0.48 |
| ▸ | NOS2 | P35228 | 5/20 | 0.47 |
| ▸ | NOS1 | P29475 | 4/20 | 0.47 |
| ▸ | NOS3 | P29474 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NOD1 | Q9Y239 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | OTC | P00480 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1932144 | 1.00 | GSR (0.53) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL3727819 | 1.00 | GSR (0.53) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL14844417 | 0.94 | GSR (0.50) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL8709636 | 0.94 | GSR (0.50) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL18741586 | 0.94 | GSR (0.50) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL28025400 | 0.89 | GSR (0.53) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL9974063 | 0.87 | GSR (0.52) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL21068053 | 0.87 | GSR (0.52) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL187909 | 0.87 | GSR (0.52) | GSRARG2ARG1NOS2NOS1 | |
| SCHEMBL25406097 | 0.86 | SLC1A3 (0.46) | GSRCYP1A2BLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 676 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12616761-B2 | CXCR4-targeting compounds | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2026-05-05 | — | — | US | claimed |
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | ALPHA-9 ONCOLOGY INC. (CA) | 2025-07-31 | — | — | US | claimed |
| WO-2025147774-A1 | COMPOSITIONS TARGETING BRADYKININ RECEPTOR B1 FOR MEDICAL IMAGING AND TREATMENT OF CANCER AND OTHER DISORDERS | ALPHA-9 ONCOLOGY INC. (CA) | 2025-07-17 | — | — | WO | claimed |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | RAYZEBIO, INC. (US) | 2025-07-10 | — | — | US | claimed |
| WO-2025137441-A1 | RADIOPHARMACEUTICALS TARGETING SOMATOSTATIN RECEPTOR 2 AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025137443-A1 | RADIOPHARMACEUTICAL COMPOSITIONS TARGETING SOMATOSTATIN RECEPTORS AND USES THEREOF | RAYZEBIO, INC. (US) | 2025-06-26 | — | — | WO | claimed |
| WO-2025068346-A1 | PHARMACEUTICAL COMBINATION OF CXCR4, PD-1 AND FAK INHIBITORS FOR TREATING CANCER | SPEXIS AG (CH) | 2025-04-03 | — | — | WO | claimed |
| WO-2025068348-A1 | PHARMACEUTICAL COMBINATION OF CXCR4 AND PD-1 INHIBITORS FOR TREATING CANCER | SPEXIS AG (CH) | 2025-04-03 | — | — | WO | claimed |
| EP-4511384-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | Provincial Health Services Authority (CA) | 2025-02-26 | — | — | EP | claimed |
| US-20240342321-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2024-10-17 | — | — | US | claimed |
| WO-2022106061-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PEPTIDE CXCR4 INHIBITOR AND A TAXANE FOR TREATING CANCER | POLYPHOR AG (CH) | 2022-05-27 | — | — | WO | claimed |
| EP-4000613-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A PEPTIDE CXCR4 INHIBITOR AND A TAXANE FOR TREATING CANCER | Polyphor Ag (CH) | 2022-05-25 | — | — | EP | claimed |
| WO-2022082312-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | PROVINCIAL HEALTH SERVICES AUTHORITY (CA) | 2022-04-28 | — | — | WO | claimed |
| WO-2022028737-A1 | ANTIMICROBIAL PEPTIDOMIMETICS | POLYPHOR AG (CH) | 2022-02-10 | — | — | WO | claimed |
| US-5516887-A | Luteinizing hormone releasing hormone antagonist peptides | Deghenghi, Romano (CH) | 1996-05-14 | — | — | US | claimed |
| EP-0540676-B1 | PEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | POLYGEN HOLDING CORP (US) | 1994-11-17 | — | — | EP | claimed |
| EP-0434675-B1 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | POLYGEN HOLDING CORPORATION (US) | 1993-09-01 | — | — | EP | claimed |
| EP-0434675-A1 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY. | EASTMAN KODAK CO (US) | 1991-07-03 | — | — | EP | claimed |
| US-4851385-A | LUTEINIZING HORMONE RELEASING HORMONE | INDIANA UNIVERSITY FOUNDATION (US) | 1989-07-25 | — | — | US | claimed |
| WO-1988009780-A2 | POLYPEPTIDE COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY | EASTMAN KODAK COMPANY (US) | 1988-12-15 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250242064-A1 | CXCR4-TARGETING COMPOUNDS, AND METHODS OF MAKING AND USING THE SAME | CXCR4, CXCL12, ACKR3 | GSR 4799/4885ARG2 1514/4885ARG1 807/4885 |
| US-20240342321-A1 | NOVEL CXCR4-TARGETING COMPOUNDS | CXCR4, CXCL12, CXCR2 | GSR 4629/4885ARG2 1805/4885ARG1 1228/4885 |
| US-12616761-B2 | CXCR4-targeting compounds | CXCR4, CXCR2, CXCR3 | GSR 4046/4885ARG2 415/4885ARG1 149/4885 |
| US-20250222146-A1 | Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof | SSTR2, SSTR4, SSTR5 | GSR 2461/4885ARG2 505/4885ARG1 517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.